Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of Assays.

doi:10.1371/journal.pone.0130796

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of Assays.

PloS one - 1 Jan 2015

Lee Jonathan A, Shinn Paul, Jaken Susan, Oliver Sarah, Willard Francis S, Heidler Steven, Peery Robert B, Oler Jennifer, Chu Shaoyou, Southall Noel, Dexheimer Thomas S, Smallwood Jeffrey, Huang Ruili, Guha Rajarshi, Jadhav Ajit, Cox Karen, Austin Christopher P, Simeonov Anton, Sittampalam G Sitta, Husain Saba, Franklin Natalie, Wild David J, Yang Jeremy J, Sutherland Jeffrey J, Thomas Craig J

Abstract excerpt

Phenotypic assays have a proven track record for generating leads that become first-in-class therapies. Whole cell assays that inform on a phenotype or mechanism also possess great potential in drug repositioning studies by illuminating new activities for the existing pharmacopeia. The National Center for Advancing Translational Sciences (NCATS) pharmaceutical collection (NPC) is the largest reported collection...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Approval

Share to Drug Evaluation, Preclinical

Share to Drug Repositioning

Share to High-Throughput Screening Assays

Share to Inhibitory Concentration 50

Share to Phenotype

Share to Small Molecule Libraries

Source

Open in PubMed Open full text

Identifiers

PMID: 26177200
DOI: 10.1371/journal.pone.0130796
PMCID: PMC4503722

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of Assays.PMID 26177200Read ↗

Innovating cancer drug discovery with refined phenotypic screens.Semantic proximity Read ↗

Open innovation for phenotypic drug discovery: The PD2 assay panel.Semantic proximity Read ↗

Phenotypic screens as a renewed approach for drug discovery.Semantic proximity Read ↗

Challenges and the Advancement in High-Throughput Screening Strategies for Cancer TherapeuticsSemantic proximity Read ↗

Phenotypic screening in cancer drug discovery - past, present and future.Semantic proximity Read ↗

Perspectives on phenotypic screening-Screen Design and Assay Technology Special Interest Group.Semantic proximity Read ↗

High-content phenotypic and pathway profiling to advance drug discovery in diseases of unmet need.Semantic proximity Read ↗

The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Phenotypic Drug Discovery.Semantic proximity Read ↗

Hit Triage and Validation in Phenotypic Screening: Considerations and Strategies.Semantic proximity Read ↗

How Phenotypic Screening Influenced Drug Discovery: Lessons from Five Years of Practice.Semantic proximity Read ↗

The Power of Sophisticated Phenotypic Screening and Modern Mechanism-of-Action Methods.Semantic proximity Read ↗

Next-generation phenotypic screening.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.